Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16154851rdf:typepubmed:Citationlld:pubmed
pubmed-article:16154851lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:16154851lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:16154851lifeskim:mentionsumls-concept:C0014822lld:lifeskim
pubmed-article:16154851lifeskim:mentionsumls-concept:C0439859lld:lifeskim
pubmed-article:16154851lifeskim:mentionsumls-concept:C0242602lld:lifeskim
pubmed-article:16154851lifeskim:mentionsumls-concept:C0439231lld:lifeskim
pubmed-article:16154851lifeskim:mentionsumls-concept:C1272689lld:lifeskim
pubmed-article:16154851pubmed:issue9lld:pubmed
pubmed-article:16154851pubmed:dateCreated2005-9-12lld:pubmed
pubmed-article:16154851pubmed:abstractTextOn day 30 after autologous peripheral blood stem cell transplantation (PBSCT), 20 patients were randomized to receive either erythropoietin at a dose of 500 U/kg/week s.c. (Epo group) or no treatment (control group). After 3 weeks, hemoglobin (p<0.0001) and serum transferrin receptor (p<0.0001) concentrations were higher in the Epo group. Hb response (+2 g/dL) was achieved in 100% vs 28% (p<0.0001) and Hb correction (> or =13 g/dL) in 70% vs 10% (p=0.0238) of the patients, respectively. This is the first randomized study showing an efficacy of erythropoietin therapy on Hb levels after autologous PBSCT.lld:pubmed
pubmed-article:16154851pubmed:languageenglld:pubmed
pubmed-article:16154851pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16154851pubmed:citationSubsetIMlld:pubmed
pubmed-article:16154851pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16154851pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16154851pubmed:statusMEDLINElld:pubmed
pubmed-article:16154851pubmed:monthSeplld:pubmed
pubmed-article:16154851pubmed:issn1592-8721lld:pubmed
pubmed-article:16154851pubmed:authorpubmed-author:BaronFrédéric...lld:pubmed
pubmed-article:16154851pubmed:authorpubmed-author:FilletGeorges...lld:pubmed
pubmed-article:16154851pubmed:authorpubmed-author:BeguinYvesYlld:pubmed
pubmed-article:16154851pubmed:authorpubmed-author:FrèrePascalePlld:pubmed
pubmed-article:16154851pubmed:authorpubmed-author:VanstraelenGa...lld:pubmed
pubmed-article:16154851pubmed:authorpubmed-author:HafraouiKaout...lld:pubmed
pubmed-article:16154851pubmed:issnTypeElectroniclld:pubmed
pubmed-article:16154851pubmed:volume90lld:pubmed
pubmed-article:16154851pubmed:ownerNLMlld:pubmed
pubmed-article:16154851pubmed:authorsCompleteYlld:pubmed
pubmed-article:16154851pubmed:pagination1269-70lld:pubmed
pubmed-article:16154851pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:16154851pubmed:meshHeadingpubmed-meshheading:16154851...lld:pubmed
pubmed-article:16154851pubmed:meshHeadingpubmed-meshheading:16154851...lld:pubmed
pubmed-article:16154851pubmed:meshHeadingpubmed-meshheading:16154851...lld:pubmed
pubmed-article:16154851pubmed:meshHeadingpubmed-meshheading:16154851...lld:pubmed
pubmed-article:16154851pubmed:meshHeadingpubmed-meshheading:16154851...lld:pubmed
pubmed-article:16154851pubmed:meshHeadingpubmed-meshheading:16154851...lld:pubmed
pubmed-article:16154851pubmed:meshHeadingpubmed-meshheading:16154851...lld:pubmed
pubmed-article:16154851pubmed:meshHeadingpubmed-meshheading:16154851...lld:pubmed
pubmed-article:16154851pubmed:meshHeadingpubmed-meshheading:16154851...lld:pubmed
pubmed-article:16154851pubmed:meshHeadingpubmed-meshheading:16154851...lld:pubmed
pubmed-article:16154851pubmed:year2005lld:pubmed
pubmed-article:16154851pubmed:articleTitleEfficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood stem cell transplantation.lld:pubmed
pubmed-article:16154851pubmed:publicationTypeLetterlld:pubmed
pubmed-article:16154851pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:16154851pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:16154851pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed